Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lipopolysaccharide degradation pathway, sometimes referred to as LPS detoxification, is not a single molecule or receptor but rather a series of enzymatic processes that break down bacterial lipopolysaccharides (LPS), which are major components of the outer membrane in Gram-negative bacteria. These pathways are crucial for host defense because intact LPS is a potent endotoxin that triggers strong inflammatory responses via receptors such as TLR4/MD2/CD14 on host cells. Key enzymes involved include acyloxyacyl hydrolase (AOAH)—which removes secondary acyl chains from lipid A, reducing its toxicity—and intestinal alkaline phosphatase, which dephosphorylates lipid A to further diminish its pro-inflammatory effects. The proper functioning of these pathways helps restore homeostasis after exposure to bacterial endotoxins and prevents excessive inflammation and related pathologies such as sepsis and chronic inflammatory diseases[3].
Enzymatic cleavage or modification of lipopolysaccharide molecules to reduce their endotoxic activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide degradation pathway.